ライフサイエンスコーパス: matrix metalloproteinase

1 e proteases or extracellularly by plasmin or matrix metalloproteinases.

2 ell migration, and reduced the expression of matrix metalloproteinases.

3 several collagens, profibrotic cytokines and matrix metalloproteinases.

4 and subsequent activation of intra-alveolar matrix metalloproteinases.

5 inflammatory and pro-fibrotic cytokines and matrix metalloproteinases.

6 ent membrane by regulating the expression of matrix metalloproteinases.

7 junctions, and suppressed the expressions of matrix metalloproteinases.

8 or ligand superfamily member 13B (TNFSF13B), matrix metalloproteinase 1 (MMP-1), MMP-2, and MMP-3.

9 Matrix metalloproteinase 1 (MMP1) is required in trachea

10 loid protein A [SAA]), inflammatory markers (matrix metalloproteinase 1 [MMP-1] and heme oxygenase 1

11 Higher levels of tissue inhibitor of matrix metalloproteinase 1 and soluble ST2 at baseline a

12 tril/valsartan decreased tissue inhibitor of matrix metalloproteinase 1 by 8% (95% confidence interva

13 ry dermal fibroblast cultures confirmed that matrix metalloproteinase 1 mRNA, MMP1, increased with ag

14 cid synthase 2 was highly expressed, whereas matrix metalloproteinase 1 was elevated in the dermal pa

15 e of collagen I and III, tissue inhibitor of matrix metalloproteinase 1, carboxyl-terminal telopeptid

16 tissue growth factor and tissue inhibitor of matrix metalloproteinase 1.

17 nic role of the cytokine tissue inhibitor of matrix metalloproteinases 1 (TIMP1) in primary pancreati

18 ange in C-reactive protein (CRP) degraded by matrix metalloproteinases 1 and 8 (CRPM) from baseline t

19 One factor, matrix metalloproteinase-1 (MMP-1), is induced in Drosop

20 The ability of AHR to control expression of matrix metalloproteinase-1 (MMP1) was analyzed.

21 y-terminal telopeptide of collagen type-I to matrix metalloproteinase-1 ratio) and with excessive myo

22 f extracellular matrix-modifying enzymes and matrix metalloproteinase-1.

23 vestigated the role of macrophage-associated matrix metalloproteinase 12 (MMP12) in the regulation of

24 actor, growth/differentiation factor 15, and matrix metalloproteinase 12.

25 Matrix metalloproteinase-12 (MMP-12) is highly upregulat

26 monocytes causing aberrant expression of the matrix metalloproteinase-12 (MMP-12).

27 ivation-induced cytokine, CHI3L1, IL-16, and matrix metalloproteinase-12 were cardiovascular proteins

28 f differentiation 40, apolipoprotein(a), and matrix metalloproteinase-12.

29 nd selective inhibitors (10d and (S)-17b) of matrix metalloproteinase 13 (MMP-13).

30 o zebrafish model to show that the epidermal matrix-metalloproteinase 13 (MMP-13) induces degeneratio

31 We show that membrane-type matrix metalloproteinase 14 (MMP14) is central to ECM de

32 Here, we reported that matrix metalloproteinase 14 (MMP14), a key pericellular

33 ng is essential for the proper activation of matrix metalloproteinase 2 (Mmp2) for follicle rupture.

34 The matrix metalloproteinase 2 (MMP2) gene has been identifi

35 tress kinase JNK mediate the accumulation of matrix metalloproteinase 2 (Mmp2), damaging the BM, whic

36 s, which correlated with a decrease in MMP2 (matrix metalloproteinase 2), MMP9, and ADAM10 (ADAM meta

37 rowth factor beta1, collagen type 4 alpha 1, matrix metalloproteinase 2, and alpha-smooth muscle acti

38 ion, cellular retinol-binding protein 1, and matrix metalloproteinase 2, compared to term and preterm

39 emodeling requires mesenchymal expression of matrix metalloproteinase 2, which is necessary for branc

40 wth factor receptor-1, protein kinase C, and matrix metalloproteinase 2.

41 proliferation, migration, and production of matrix metalloproteinase 2; treatment with MDM2 inhibito

42 lanoma cells by modulating the activities of matrix metalloproteinases 2 and 9 (MMP-2 and MMP-9).

43 osure to tumor-associated proteases, such as matrix metalloproteinases 2 and 9, the coiled-coil pepti

44 including collagen 1 and 3, fibronectin, and matrix metalloproteinases 2 and 9, were up-regulated in

45 wth factor (VEGF), Interleukin 6 (IL-6), and matrix metalloproteinase-2 (MMP-2) were measured using a

46 TGF-beta1), connective tissue growth factor, matrix metalloproteinase-2 (MMP-2), MMP-14, endoglin (EN

47 okinase-type plasminogen activator (uPA) and matrix metalloproteinase-2 (MMP-2).

48 In vitro, Meg3 regulated the production of matrix metalloproteinase-2 (MMP-2).

49 p, and Reck could suppress the expression of matrix metalloproteinase-2 (Mmp2) and Mmp9, which could

50 A matrix metalloproteinase-2 (MMP2) sensitive self-assembl

51 pendent mitochondrial Ca(2+) uptake promotes matrix metalloproteinase-2 activity and cell motility by

52 f alternative activation, iii) cytokine, iv) matrix metalloproteinase-2 activity, v) fibrosis, and vi

53 Near-apneic group showed significantly less matrix metalloproteinase-2 and -9 activity.

54 A monoclonal antibody was raised against a matrix metalloproteinase-2 and -9 specific cleavage site

55 well as connective tissue growth factor and matrix metalloproteinase-2 expression.

56 Pathogenic rise of collagenolytic matrix metalloproteinase-2 in biofilm-infected wound-edg

57 Levels of IL-10, IL-6, and matrix metalloproteinase-2 were significantly increased,

58 mpared with sham, and its activation induced matrix metalloproteinase-2, which enhanced GB pathogenes

59 g upregulation of its downstream target gene matrix metalloproteinase-2.

60 es, contractile myofibroblasts, glial cells, matrix metalloproteinases-2 and -9, and collagen type I,

61 e senescence-associated secretory phenotype (matrix metalloproteinases-2/9, C-X-C motif chemokine lig

62 ed to investigate the role of proteolysis by matrix metalloproteinase 20 (MMP20) in regulating the in

63 Furthermore, this study elucidated that matrix metalloproteinase-20 is a critical regulator of t

64 TWIST1 induced matrix metalloproteinase 3 (MMP3) expression without dir

65 jury also increased the levels/activation of matrix metalloproteinase 3 and 9.

66 ate immune activation, in particular YKL-40, matrix metalloproteinase 3, macrophage inflammatory prot

67 barrier repair (matrix metalloproteinase 7, matrix metalloproteinase 3, the integrins beta6 and beta

68 ype in cardiac fibroblasts, suppressing MMP (matrix metalloproteinase)-3 and MMP-8 synthesis and indu

69 Matrix metalloproteinase-3 (MMP-3) participates in norma

70 though CAFs promoted prostate cancer growth, matrix metalloproteinase-3 (MMP-3) was lower in CAFs but

71 ression of late responsive genes such as the matrix metalloproteinase-3 and the RE1 silencing transcr

72 +) matrix resulted in the strongest IL-6 and matrix metalloproteinase-3 release, and was even more pr

73 Expression of matrix metalloproteinase 7 (MMP7), an AP-1 target, was a

74 s associated with epithelial barrier repair (matrix metalloproteinase 7, matrix metalloproteinase 3,

75 RATIONALE: Matrix metalloproteinase-7 (MMP-7) has been implicated i

76 fic PCR array assays revealed that WNT5A and matrix metalloproteinase-7 (MMP7) were upregulated by FO

77 lationship between the expression of FXR and matrix metalloproteinase-7 (MMP7), a collagenase and sig

78 ), angiopoietin-2 (related to angiogenesis), matrix metalloproteinase-7 (related to extracellular mat

79 splayed similar CCL expression and suggested matrix metalloproteinase-7 and MMP9 as possible extracel

80 h as Bcl-2 (B-cell lymphoma 2), c-Myc, MMP7 (matrix metalloproteinase-7), and cyclin D1in vitro and i

81 or repression of Kaiso target genes, such as matrix metalloproteinase-7.

82 C4-Fc (truncated N-cadherin), or deletion of matrix-metalloproteinase-7 (Mmp-7) reduced VSMC apoptosi

83 Because CGPQG IWGQC can be cleaved by matrix metalloproteinase 8 (MMP-8), minocycline hydrochl

84 e across all analyses was MMP8, encoding the matrix metalloproteinase 8, which is a regulator of inna

85 gate if a point-of-care (PoC) test of active matrix metalloproteinase-8 (aMMP-8) predicts levels of i

86 endently evaluated two protein coding genes, matrix metalloproteinase-8 (MMP-8) and transcription fac

87 4D), peptidylarginine deiminase 2 (PAD2) and matrix metalloproteinase-8 (MMP-8) in gingival crevicula

88 oxidative glutathione ratio [GSH/GSSG]), and matrix metalloproteinase-8 (MMP-8) levels; and histopath

89 ovel prototype biosensor to measure salivary matrix metalloproteinase-8 (MMP-8) using specific antibo

90 tial salivary periodontal biomarkers (active matrix metalloproteinase-8 [aMMP-8], polymorphonuclear l

91 the control group 3 and 6 months after SRP, matrix metalloproteinase-8 level decreased in the test g

92 fibrosis and platelet markers such as MMP-8 (matrix metalloproteinase-8) and TIMP-1 (tissue inhibitor

93 gen and interleukin-1beta, and downregulated matrix metalloproteinase-8, whereas periodontal bone lev

94 Matrix metalloproteinase 9 (MMP-9) antisense oligonucleo

95 Cathepsin B increased the activity of matrix metalloproteinase 9 (MMP-9), an enzyme involved i

96 autoimmune skin-blistering disease, involves matrix metalloproteinase 9 (MMP-9), IL-17, and IL-23 rel

97 llagen I were reduced as was the activity of matrix metalloproteinase 9 (MMP-9).

98 proinflammatory cytokine TNFalpha stimulates matrix metalloproteinase 9 (MMP9) at the ocular surface

99 Matrix metalloproteinase 9 (MMP9) contributes to this pr

100 ated the expression of the metalloproteinase matrix metalloproteinase 9 (MMP9) in human breast cancer

101 Matrix metalloproteinase 9 (MMP9) is a member of a large

102 Matrix metalloproteinase 9 (MMP9) is expressed in teeth

103 Further, mutation of matrix metalloproteinase 9 (mmp9) results in delayed gro

104 ced microglia activation and redox-sensitive matrix metalloproteinase 9 (MMP9) stimulation, leading t

105 Matrix metalloproteinase 9 (MMP9), which degrades NGF, w

106 zes combretastatin A4 nanodrug (CA4-NPs) and matrix metalloproteinase 9 (MMP9)-activated doxorubicin

107 activity and differentiation, in particular matrix metalloproteinase 9 (MMP9).

108 It is a major inducer of matrix metalloproteinase 9 and is selectively toxic for

109 Additionally, levels of matrix metalloproteinase 9 and the chemokines C-C motif

110 VIP gene haploinsufficiency results in lower matrix metalloproteinase 9 expression, and reduced migra

111 C-terminal region, via the action of MMP-9 (matrix metalloproteinase 9).

112 or bearing as well as expression of IL-8 and matrix metalloproteinase 9, ankle loading decreased them

113 A 4-biomarker signature (matrix metalloproteinase 9, S100A8/S100A9, cathepsin D,

114 t testis, likely via proteolytic cleavage of matrix metalloproteinase 9.

115 vated receptor gamma, and reducing Snail and matrix metalloproteinase 9.

116 ially by modulating the activity of secreted matrix metalloproteinases 9 (MMP-9).

117 he objective of this study is to investigate Matrix Metalloproteinase-9 (MMP-9) as predictive biomark

118 The dysregulation of matrix metalloproteinase-9 (MMP-9) has been implicated i

119 sma and ELISA demonstrates reduced levels of matrix metalloproteinase-9 (MMP-9) in the plasma and bra

120 Matrix metalloproteinase-9 (MMP-9) is required for struc

121 ranscription factor 4 (Oct-4) expression and matrix metalloproteinase-9 (MMP-9) secretion by these ce

122 superoxide dismutase (SOD), catalase (CAT), matrix metalloproteinase-9 (MMP-9), and cardiac Troponin

123 polarization, and (iv) TNF-alpha-stimulated matrix metalloproteinase-9 (MMP9) expression and activit

124 Remarkably, proteinases including matrix metalloproteinase-9 (Mmp9) released from endothel

125 ulation of tumor-secreted factors, including matrix metalloproteinase-9 (MMP9), fibronectin (FN), and

126 In addition, PKal inhibition reduced matrix metalloproteinase-9 activity in brain following s

127 T cells display helper function for monocyte matrix metalloproteinase-9 and tissue factor production

128 regulatory factor 3, which directly induced matrix metalloproteinase-9 expression.

129 beyond drug clearance.SIGNIFICANCE STATEMENT Matrix metalloproteinase-9 inhibition appears to attenua

130 activity of the BBB-degrading cyclophilin A-matrix metalloproteinase-9 pathway(19) in cerebrospinal

131 Osteopontin and matrix metalloproteinase-9 were confirmed inside EV.

132 groups of EC and NS (myeloperoxidase [MPO], matrix metalloproteinase-9) as well as between DS and EC

133 ic factors in tumors, including IL-1beta and matrix metalloproteinase-9, and we found upregulation of

134 erleukin-6, tumor necrosis factor-alpha, and matrix metalloproteinase-9, suggesting that KC may have

135 uld be attributed to changes in TGF-beta and matrix metalloproteinase-9, the downstream effectors of

136 nism involving the PI3K/AKT/mTOR pathway and matrix metalloproteinase-9.

137 localization and activity of membrane type 1-matrix metalloproteinase, a key factor for extracellular

138 d TJP levels to that of controls and reduced matrix metalloproteinase activation in the sub-acute sta

139 n bTBI through a pathway involving increased matrix metalloproteinase activation.

140 However, intra-alveolar matrix metalloproteinase activity and levels of the matr

141 We found that matrix metalloproteinase activity is not required for ma

142 ilation decreased histologic lung injury and matrix metalloproteinase activity, and prevented the exp

143 tro, there was poor EVT invasion and reduced matrix metalloproteinase activity, reinforcing their cri

144 ) to N-methyl-D-aspartate (NMDA) ratios, and matrix metalloproteinase activity.

145 also displayed significantly decreased MMP (matrix metalloproteinases) activity in the aorta (mean d

146 GM6001, an inhibitor of matrix metalloproteinase, alleviated UA-induced glycocal

147 and caries could be detected using an active matrix metalloproteinase (aMMP)-8 chairside test in Finn

148 ormations upon interacting with integrins or matrix metalloproteinase and DNA deformations upon prote

149 dal signalling-and therefore the activity of matrix metalloproteinases and basement membrane perforat

150 , altered cellular bioenergetics, suppressed matrix metalloproteinases and chemokine receptors, and t

151 which were marked by increased expression of matrix metalloproteinases and degradation of the basemen

152 on-T2/proinflammatory (with higher levels of matrix metalloproteinases and inflammatory cytokines).

153 level of apoptosis, suppressed expression of matrix metalloproteinases and reduction in MDSCs infiltr

154 of ORP2 resulting in proteolytic cleavage by matrix metalloproteinases, and reduced activity of VEGFR

155 ar mediators, we identified TGF-beta and the matrix metalloproteinases as therapeutic targets whose m

156 metalloproteinase activity and levels of the matrix metalloproteinase cleavage product soluble recept

157 vated protein kinase (MAPK), down-regulating matrix metalloproteinases, collagen, and IL6 secretion f

158 Thus, matrix metalloproteinase-directed processing of PTHrP di

159 GFbeta signaling and increased expression of matrix metalloproteinases driving the induction of c-Jun

160 Our findings underscore the key role of matrix metalloproteinases during the progression of aort

161 eling phase of wound healing, with increased matrix metalloproteinase expression and reduced collagen

162 edifferentiation and cell death in SMCs, and matrix metalloproteinase expression in macrophages.

163 on, basement membrane degradation, decreased matrix metalloproteinase expression, as well as clonogen

164 bnormalities in fibrillin-1 accumulation and matrix metalloproteinase expression.

165 adopodia are dynamic protrusions that harbor matrix metalloproteinases for pericellular matrix degrad

166 Matrix metalloproteinases have a broad spectrum of subst

167 Furthermore, inhibiting matrix metalloproteinases in ACM reversed ACM's effect o

168 it progenitor cell recruitment, but systemic matrix metalloproteinase inhibition might prevent efflux

169 rthermore, treatment with the broad-spectrum matrix metalloproteinase inhibitor batimastat (BB94) or

170 Doxycycline, a nonselective matrix metalloproteinases inhibitor, was reported to imp

171 he SDC4 ectodomain, mimicking the effects of matrix metalloproteinase inhibitors.

172 g M1-AQP4 isoform display higher activity of matrix metalloproteinases, making them more invasive.

173 ling to simulate 1-y clinical function, or a matrix metalloproteinase-mediated aging process.

174 matrix is regulated by catalytic activity of matrix metalloproteinases MMP-2,9.

175 g1l, gilz, and socs3, and development genes, matrix metalloproteinases mmp-9 and mmp-13, while cortis

176 inding protein (FABP) 2, fas ligand (FASLG), matrix metalloproteinase (MMP) 1, MMP7, soluble CD14 (sC

177 lage matrix is accompanied by an increase in matrix metalloproteinase (MMP) 13, partially because of

178 ascular endothelial growth factor (VEGF) and matrix metalloproteinase (MMP) 13.

179 -regulation of interleukin 1 beta (IL1B) and matrix metalloproteinase (MMP) 3 in the cecum.

180 lloproteinase with thrombospondin motifs 4-, matrix metalloproteinase (MMP) 9-, and MMP13-positive ce

181 Excessive matrix metalloproteinase (MMP) activity is emerging as a

182 ting and quantitative RT-PCR with subsequent matrix metalloproteinase (MMP) activity.

183 glycoprotein that functions as an inducer of matrix metalloproteinase (MMP) expression in fibroblasts

184 oteins that all inhibit members of the large matrix metalloproteinase (MMP) family but differ in thei

185 -2, and phosphorylated NF-kappaB, as well as matrix metalloproteinase (MMP) family members including

186 Since their discovery, the matrix metalloproteinase (MMP) family proteases have bee

187 Certain matrix metalloproteinase (MMP) family proteins have been

188 fy an association between a variant within a Matrix metalloproteinase (MMP) gene member, MMP20, and 1

189 In contrast, use of a broad-spectrum matrix metalloproteinase (MMP) inhibitor (GM6001) to blo

190 The design of selective matrix metalloproteinase (MMP) inhibitors that also poss

191 We further show that the matrix metalloproteinase (MMP) mmp14a is required in pio

192 bolaamphiphiles (RBA) capable of exposing a matrix metalloproteinase (MMP) substrate on the surface

193 be rescued with collagen IV overexpression, matrix metalloproteinase (MMP), and Furin inhibitors in

194 lted in down-regulation of the expression of matrix metalloproteinase (MMP)-1, MMP-3, MMP-10, and MMP

195 this study, we identified elevated levels of matrix metalloproteinase (MMP)-12 in gingival tissue of

196 Macrophage elastase [matrix metalloproteinase (MMP)-12] is the most upregulat

197 , and collagen 1 and increased expression of matrix metalloproteinase (MMP)-2 and -9.

198 ibitor of matrix metalloproteinase (TIMP)-1, matrix metalloproteinase (MMP)-2, MMP-9, Galectin-3 (Gal

199 gration, via transcriptional upregulation of matrix metalloproteinase (MMP)-2.

200 Matrix metalloproteinase (MMP)-3 expression in CTGF-deli

201 he association between the concentrations of matrix metalloproteinase (MMP)-8 and -9 in gingival crev

202 Matrix metalloproteinase (MMP)-8 and -9 released by degr

203 th the presence of proinflammatory mediators matrix metalloproteinase (MMP)-8 and interleukin (IL)-1b

204 This study evaluates levels of matrix metalloproteinase (MMP)-8, MMP-9, and tissue inhi

205 smoking on salivary periodontal biomarkers, matrix metalloproteinase (MMP)-8, MMP-9, tissue inhibito

206 (iNOS), bone morphogenetic protein (BMP)-2, matrix metalloproteinase (MMP)-8, tissue inhibitor of MM

207 raphic peri-implant parameters and levels of matrix metalloproteinase (MMP)-9 and interleukin (IL)-1b

208 ide synthase (iNOS), cyclooxygenase (COX)-2, matrix metalloproteinase (MMP)-9 and tissue inhibitor of

209 ssion in the tumor cells negatively affected matrix metalloproteinase (MMP)-9 gene expression.

210 to investigate levels of salivary and serum matrix metalloproteinase (MMP)-9, myeloperoxidase (MPO),

211 e-like traits, including rounded morphology, matrix metalloproteinase (MMP)-independent migration, an

212 breast cancer yet may increase the level of matrix metalloproteinases (MMP) -2 and -9, which increas

213 ctivated by extracellular proteases, such as matrix metalloproteinases (MMP) that are overexpressed i

214 such as the translocator protein (TSPO) and matrix metalloproteinases (MMP), may serve as specific i

215 tly (95% level) were interleukin (IL)-1beta, matrix metalloproteinases (MMP)-1, MMP-3, MMP-8, MMP-9,

216 ation through a 3D extracellular matrix in a matrix metalloproteinases (MMP)-dependent fashion.

217 biting 5 targets of 4 main protease classes: matrix metalloproteinases (MMP-14, a predominant target

218 sses of proteases: plasmin, cathepsin L, and matrix metalloproteinases (MMP-2 and MMP-9).

219 udin-5 and occludin; increased expression of matrix-metalloproteinases (MMP)-3 and -9 and enhanced li

220 also associated with higher plasma levels of matrix metalloproteinases ([MMP]-1, -2, -7, -8, and -9)

221 RATIONALE: Macrophage elastase (matrix metalloproteinase [MMP]-12) is a potent protease

222 Concentrations of active enzymes (matrix metalloproteinase [MMP]-8, elastase, and sialidas

223 factor [TNF]-alpha, interleukin [IL]-1beta, matrix metalloproteinase [MMP]-8, MMP-9, and cathepsin D

224 -6], tumor necrosis factor alpha [TNFalpha], matrix metalloproteinase [MMP]-9, macrophage migration i

225 the stress kinase JNK and production of the matrix metalloproteinase MMP1.

226 ing of feedback mechanisms between CAV1, the matrix metalloproteinase MMP14 and oestrogen receptors.

227 1 (PROX1), which relieved repression of the matrix metalloproteinase MMP14.

228 se-8, neutrophil elastase, legumain, and two matrix metalloproteinases (MMP2 and MMP9), we demonstrat

229 taminase-2), and ECM turnover genes/enzymes (matrix metalloproteinases-MMP2,14 and their inhibitors-T

230 of TMJ fibrocartilage matrix via E2-induced matrix metalloproteinases MMP9 and MMP13.

231 ulator of G protein signalling 2 (RGS2), and matrix metalloproteinases (MMPs) 1, 8, and 10 were also

232 the presence of elevated proteases, such as matrix metalloproteinases (MMPs) and a disintegrin and m

233 en hydrogen sulfide (H2S), microRNAs (miRs), matrix metalloproteinases (MMPs) and poly-ADP-ribose-pol

234 The induction of matrix metalloproteinases (MMPs) and reduction in tissue

235 ing cued reinstatement depends on activating matrix metalloproteinases (MMPs) and selective chemogene

236 Matrix metalloproteinases (MMPs) and the related familie

237 lagen, but also ECM-degrading enzymes called matrix metalloproteinases (MMPs) and their inhibitors (T

238 rimarily known as an endogenous inhibitor of matrix metalloproteinases (MMPs) and thus associated wit

239 Matrix metalloproteinases (MMPs) are associated with dec

240 Matrix metalloproteinases (MMPs) are central to cancer d

241 Matrix metalloproteinases (MMPs) are extracellular enzym

242 Matrix metalloproteinases (MMPs) are extracellular prote

243 or modulators of ECM structure and function, matrix metalloproteinases (MMPs) are highly expressed in

244 Although matrix metalloproteinases (MMPs) are implicated in the r

245 Matrix metalloproteinases (MMPs) are inducible endopepti

246 Matrix metalloproteinases (MMPs) are involved in a spect

247 A few matrix metalloproteinases (MMPs) are known to support th

248 We assessed host matrix metalloproteinases (MMPs) as the BV-associated se

249 nase-type plasminogen activator (uPA) and/or matrix metalloproteinases (MMPs) as well as some of the

250 Under pathological conditions, matrix metalloproteinases (MMPs) can disrupt the BBB thr

251 Matrix metalloproteinases (MMPs) can proteolytically cle

252 Matrix metalloproteinases (MMPs) contribute to conventio

253 Matrix metalloproteinases (MMPs) contribute to the break

254 Matrix metalloproteinases (MMPs) degrade extracellular m

255 Matrix metalloproteinases (MMPs) degrade several ECM com

256 To many of us in the field, working on matrix metalloproteinases (MMPs) has felt like riding a

257 Certain matrix metalloproteinases (MMPs) have the ability to deg

258 viously reported doxycycline, a nonselective matrix metalloproteinases (MMPs) inhibitor, to attenuate

259 Aberrant activation of matrix metalloproteinases (MMPs) is a common feature of

260 Increased activity of matrix metalloproteinases (MMPs) is associated with wors

261 Matrix metalloproteinases (MMPs) play key roles in the d

262 cial to these processes is the production of matrix metalloproteinases (MMPs) that modify the microen

263 s known to bind or inhibit the activities of matrix metalloproteinases (MMPs), a family of zinc-depen

264 gate the levels of neutrophil elastase (NE), matrix metalloproteinases (MMPs), and myeloperoxidase (M

265 EGFR activation revealed the requirement of matrix metalloproteinases (MMPs), EGFR ligands and calci

266 roteinases (TIMPs) are natural inhibitors of matrix metalloproteinases (MMPs), enzymes that contribut

267 Matrix metalloproteinases (MMPs), especially MMP-13, are

268 cyte-derived M exposed to NE releases active matrix metalloproteinases (MMPs), increase expression of

269 and mouse studies have implicated roles for matrix metalloproteinases (MMPs), particularly macrophag

270 ression of fibronectin- and laminin-specific matrix metalloproteinases (MMPs), particularly MMP-3, wa

271 cancer cells must exocytose proteases, like matrix metalloproteinases (MMPs), that are key in extrac

272 1 (TIMP-1), the endogenous inhibitor of the matrix metalloproteinases (MMPs), to be translocated to

273 of the JNK pathway and induces expression of matrix metalloproteinases (MMPs), which are necessary fo

274 Monocytes secrete matrix metalloproteinases (MMPs), which have key roles i

275 gen, vascular smooth muscle cells (VSMC) and matrix metalloproteinases (MMPs).

276 ion of several downstream targets, including matrix metalloproteinases (MMPs).

277 e it is coupled with increased expression of matrix metalloproteinases (MMPs).

278 truction via the induction and activation of matrix metalloproteinases (MMPs).

279 trix components and their regulators such as matrix metalloproteinases (MMPs).

280 senescent tumor cells through activation of matrix metalloproteinases (MMPs).

281 failed to achieve selectivity against human matrix metalloproteinases (MMPs).

282 duction and is involved in the activation of matrix metalloproteinases (MMPs).

283 es, exemplified with the tumor-overexpressed matrix metalloproteinase MT1-MMP as a target.

284 n outgrowth and the targeted delivery of the matrix metalloproteinase MT1-MMP via endosomal transport

285 (GM6001) to block endogenous membrane type 1 matrix metalloproteinase (MT1-MMP) activity does not ful

286 ited impaired trafficking of membrane type 1 matrix metalloproteinase (MT1-MMP) and EGF receptor (EGF

287 Membrane type 1-matrix metalloproteinase (MT1-MMP) and tumor necrosis fa

288 Membrane-type 1 matrix metalloproteinase (MT1-MMP) is a membrane-bound M

289 Blocking of matrix metalloproteinases or tyrosine kinases are novel

290 These signaling changes inhibit cofilin and matrix metalloproteinases reducing in vitro and in vivo

291 s due to increased invadopodia formation and matrix metalloproteinase secretion.

292 are needed for cell protrusion formation and matrix metalloproteinases secretion during cell invasion

293 In contrast, the matrix metalloproteinase/TACE (tumor necrosis factor-alp

294 nocytes IL-1beta increases the expression of matrix metalloproteinases, tenascin-C and Sox9 and decre

295 , 7, 8, 9, 12), MPO, and tissue inhibitor of matrix metalloproteinase (TIMP)-1 were analyzed using mu

296 one, soluble ST2 (sST2), tissue inhibitor of matrix metalloproteinase (TIMP)-1, matrix metalloprotein

297 the mature PTHrP1-36 hormone is processed by matrix metalloproteinases to yield a stable product, PTH

298 of proinflammatory cytokines, chemokines and matrix metalloproteinases, which together facilitated T

299 at are structurally similar to the family of matrix metalloproteinases with critical roles in damage

300 that simultaneous modulation of TGF-beta and matrix metalloproteinases would be more effective in tre